Literature DB >> 20953557

miR-126 and miR-126*: new players in cancer.

Jeannette Meister1, Mirko H H Schmidt.   

Abstract

Cancer progression is characterized by autarky in growth signals, insensitivity to growth-restrictive signals, evasion of apoptosis, a limitless potential to replicate, sustained angiogenesis, and tissue invasion, including metastasis. The regulation of these cellular processes relies on a fine-tuned control of molecular signal cascades. In recent years, short noncoding RNAs termed microRNAs (miRNAs) have been described as a novel class of molecular regulators. These affect various signaling cascades during the progression of neoplastic diseases by the regulation of gene expression on the post-transcriptional level. The novel endothelial cell-derived secreted protein epidermal growth factor-like domain 7 (EGFL7) has been suggested to control vascular tubulogenesis. Further, the two biologically active miRNAs miR-126 and its complement miR-126*, which are encoded by intron 7 of the egfl7 gene, have been described to mediate vascular functions. Knock-out studies in zebrafish and mice suggested a major role of miR-126 in angiogenesis and vascular integrity, which was mediated by the repression of inhibitors of VEGF-induced proliferation in endothelial cells. Recent studies revealed the distribution and function of miR-126 and miR-126* in various types of cancer, and assigned a role to both miRNAs as suppressors of tumor formation. Indeed, miR-126 and miR-126* have been reported to impair cancer progression through signaling pathways that control tumor cell proliferation, migration, invasion, and survival. Conversely, miR-126 and miR-126* may have a supportive role in the progression of cancer as well, which might be mediated by the promotion of blood vessel growth and inflammation. In this work, we will summarize the current knowledge on functions of miR-126/miR-126* that are relevant for cancer formation, and we will discuss their potential clinical use as predictive markers of survival and application as novel therapeutic targets for the treatment of neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20953557      PMCID: PMC5763667          DOI: 10.1100/tsw.2010.198

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  88 in total

1.  The expression profiles of microRNAs in Kaposi's sarcoma.

Authors:  Xiu-Juan Wu; Xiong-Ming Pu; Zong-Feng Zhao; Ya-Nan Zhao; Xiao-Jing Kang; Wei-Dong Wu; Yun-Min Zou; Cao-Ying Wu; Yuan-Yuan Qu; De-Zhi Zhang; Yan-Yan Feng; Jian-Yong Liu
Journal:  Tumour Biol       Date:  2014-10-01

2.  Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma.

Authors:  Ela Toxopeus; N Lynam-Lennon; K Biermann; G Dickens; P E de Ruiter; Jjb van Lanschot; J V Reynolds; Bpl Wijnhoven; J O'Sullivan; Ljw van der Laan
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-07

3.  Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma.

Authors:  Megan E McNally; Amy Collins; Sylwia E Wojcik; James Liu; Jon C Henry; Jinmai Jiang; Thomas Schmittgen; Mark Bloomston
Journal:  HPB (Oxford)       Date:  2012-07-04       Impact factor: 3.647

4.  Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.

Authors:  Ghada Al-Kafaji; Harun Muayad Said; Mahmood Abduljalil Alam; Ziad Tarraq Al Naieb
Journal:  Oncol Lett       Date:  2018-05-22       Impact factor: 2.967

Review 5.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis.

Authors:  Keiko Mizuno; Hiroko Mataki; Naohiko Seki; Tomohiro Kumamoto; Kazuto Kamikawaji; Hiromasa Inoue
Journal:  J Hum Genet       Date:  2016-08-04       Impact factor: 3.172

Review 6.  Regulation of cancer metastasis by cell-free miRNAs.

Authors:  Maša Alečković; Yibin Kang
Journal:  Biochim Biophys Acta       Date:  2014-10-28

7.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

8.  A one-two punch of miR-126/126* against metastasis.

Authors:  Guangwen Ren; Yibin Kang
Journal:  Nat Cell Biol       Date:  2013-03       Impact factor: 28.824

9.  MiR-126 Regulates the ERK Pathway via Targeting KRAS to Inhibit the Glioma Cell Proliferation and Invasion.

Authors:  Yang Li; Yunqian Li; Pengfei Ge; Chengyuan Ma
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

10.  Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo.

Authors:  Hyemee Kim; Nivedita Banerjee; Ryan C Barnes; Catherine M Pfent; Stephen T Talcott; Roderick H Dashwood; Susanne U Mertens-Talcott
Journal:  Mol Carcinog       Date:  2016-04-06       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.